Cellectar BioSciences Inc. has outlined key developments in its phospholipid drug conjugate (PDC) platform, highlighting progress in multiple oncology therapeutic programs. The company is advancing its pipeline with a focus on targeted radiotherapeutics, reporting readiness for a Phase 1b/2a study with an Auger emitting therapeutic for triple negative breast cancer and finalizing the investigational new drug $(IND)$ application for CLR 225 (actinium) in solid tumors. Preclinical data with radiotherapies using isotopes such as Lu177, Pb212, and At211 were also noted. Additionally, Cellectar is optimizing the regulatory strategy for iopofosine I 131, aiming for conditional market authorization in Europe and accelerated approval in the U.S. based on positive Phase 2b data in Waldenstrom's macroglobulinemia. The company plans to pursue further development and commercialization partnerships in the U.S. and EU, as well as collaborations to support asset development. You can access the full presentation through the link below.